Table 3.

Adjusted Cox Proportional Hazards Regression Model of Clinical Factors and Risk of Disease Progression (n = 1,088)

Factor	OR	95% CI	P
BMI
Normal/underweight	1.0
Overweight	0.97	0.70 to 1.32	.83
Obese	0.98	0.70 to 1.37	.91
Race
White	1.00
Black	0.92	0.61 to 1.38	.68
Hispanic	0.87	0.56 to 1.35	.53
Asian/other	1.48	0.83 to 2.63	.18
Age (years) at start of treatment (continuous)	0.98	0.96 to 0.99	< .01
Time (months) from start of NC to surgery	1.10	1.01 to 1.20	.02
Menopausal status
Postmenopausal	1.00
Premenopausal	0.79	0.54 to 1.16	.23
Perimenopausal	0.52	0.24 to 1.14	.10
NC regimen
Nontaxane based	1.00
Taxane based	1.12	0.80 to 1.56	.50
Hormone receptor status
ER and PR negative, no endocrine therapy	1.00
ER and/or PR positive, no endocrine therapy	0.97	0.63 to 1.49	.89
ER and/or PR positive, endocrine therapy	0.44	0.33 to 0.60	< .01
Nuclear grade
Grade 1 or 2	1.00
Grade 3	1.76	1.27 to 2.45	< .01
No. of involved lymph nodes (continuous)	1.10	1.08 to 1.13	< .01
Clinical stage
Stage I or II	1.0
Stage III	1.43	1.08 to 1.90	.01
pCR
Yes	1.0
No	4.72	2.40 to 9.41	< .01

Abbreviations: OR, odds ratio; BMI, body mass index; NC, neoadjuvant chemotherapy; ER, estrogen receptor; PR, progesterone receptor; pCR, pathologic complete response.